All In Biotech

Drug Trial Radar · NCT03838575

ROSSINI 2 - Reduction of Surgical Site Infection Using Several Novel Interventions

A Phase III, Multi-arm, Multi-stage (MAMS), Pragmatic, Blinded (Patient and Outcome Assessor), Multicentre, Randomised Controlled Trial (RCT) With an Internal Pilot, to Evaluate the Use of Several In-theatre Interventions, Used Alone or in Combination, to Reduce SSI Rates in Patients Undergoing Abdominal Surgery.

Last checked: Nov 19, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 6,610 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

6,610

Planned (sponsor's estimate)

Start

Mar 1, 2019

Primary completion

May 2023

Study completion Aug 2023

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Health Research, United Kingdom; University College, London
First posted
Feb 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ROSSINI 2 is a phase III, multi-arm, multi-stage (MAMS) pragmatic, blinded (patient and outcome assessor), multicentre, randomised controlled trial (RCT) with an internal pilot, to evaluate the use of several in-theatre interventions, used alone or in combination, to reduce SSI rates in patients undergoing surgery.

Conditions

  • Surgical Site Infection
  • Surgical Wound Infection
  • Surgery--Complications
  • Surgery

Interventions

  • 2% alcoholic chlorhexidine skin prep (SKIN PREP)Drug

    This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).

  • Iodophor Antimicrobial Incise Drapes (DRAPE)Device

    Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment. This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied.

  • Gentamicin-impregnated implants/ sponges (SPONGE)Device

    This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.

  • NONE (Control)Other

    Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep. No drapes or sponges of any kind may be used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SSI rate up to 30 days after surgery as defined according to the 2017 Centers for Disease Control (CDC) and Prevention Criteria.Time frame: 30 days post surgery

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth Hospital Birmingham

    Birmingham, United Kingdom · Recruiting

  • Countess of Chester Hospital

    Chester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.